Page 6 - Idacio Adalimumab
P. 6

IDACIO  en presentación de 40 mg/0,8 ml Autoinyector, que se ajusta a las necesidades
                           ®
                   de sus pacientes
                                      4







































                    1.  Magnenat L, Palmee A, Fremaux C, D’Amici F, Terlizzese M, Rossi M, Chevalet L, et al. Demonstration of physicochemical and functional
                      similarity between de proposed biosimilar adalimumab MSB11022 and Humira . mAbs, 9:1, 127-139, DOI: 10.1080/19420862.2016.1259046
                                                                               ®
                    2.  Hyland E, et al. Br J Clin Pharmacol. 82:983-993. 2016
                    3.  Hercogová J, Papp KA, Chyrok V, Ullmann M, Vlacho P, Edwards CJ. AURIEL-PsO: A randomised, double-blind Phase III equivalence trial to
                      demonstrate the clinical similarity of proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic
                      plaque-type psoriasis. Br J Dermatol. doi: 10.111/bjd.18220. Jun 17. 2019
                    4.  IDACIO  FT. 2019.
                           ®

                                         Fresenius Kabi Chile
                                         Carlos Fernández 244,
                                         San Joaquín, Santiago - Chile
                                         Tel.: 2462 70 00 - Fax: 2551 65 53
                                         www.fresenius-kabi.com/cl/
      MK-MPIV-105
   1   2   3   4   5   6   7